| Status | Study |
| Recruiting |
Study Name: Cabozantinib-S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Condition: Endometrial Adenosquamous Carcinoma Endometrial Clear Cell Aden Date: 2013-09-03 Interventions: Drug: Cabozantinib S-malate Gi |
| Active, not recruiting |
Study Name: Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer Condition: Endometrial Adenocarcinoma Endometrial Adenosquamous Carcinoma Date: 2012-07-15 Interventions: Biological: Dalantercept Given |
| Active, not recruiting |
Study Name: Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Condition: Endometrial Adenocarcinoma Endometrial Adenosquamous Carcinoma Date: 2011-09-24 Interventions: Drug: Carboplatin Given IV |
| Active, not recruiting |
Study Name: Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer Condition: Endometrial Adenocarcinoma Endometrial Adenosquamous Carcinoma Date: 2011-03-01 Interventions: Drug: Akt Inhibitor MK2206 Giv |
| Completed |
Study Name: Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Condition: Endometrial Adenocarcinoma Endometrial Adenosquamous Carcinoma Date: 2010-09-25 Interventions: Biological: Trebananib Given IV Other Names: |
| Completed |
Study Name: Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer Condition: Endometrial Adenocarcinoma Endometrial Adenosquamous Carcinoma Date: 2010-05-27 Interventions: Drug: Cediranib Maleate Given |
| Completed |
Study Name: Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer Condition: Endometrial Adenocarcinoma Endometrial Adenosquamous Carcinoma Date: 2009-11-10 Interventions: Other: Diagnostic Laboratory Biomarker Analysis |
| Active, not recruiting |
Study Name: Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Condition: Endometrial Adenocarcinoma Endometrial Adenosquamous Carcinoma Date: 2009-09-12 Interventions: Biological: Bevacizumab Given |
| Completed |
Study Name: Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer Condition: Endometrial Adenocarcinoma Endometrial Adenosquamous Carcinoma Date: 2009-01-09 Interventions: Drug: Gemcitabine Hydrochloride Given IV Other Names |
| Active, not recruiting |
Study Name: Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer Condition: Endometrial Adenosquamous Carcinoma Endometrial Clear Cell Aden Date: 2007-12-15 Interventions: Drug: Cisplatin Given IV or IP |